Know Cancer

forgot password

A Phase II Study of 17 -AAG in Patients With RelapsedRefractory CD30 + Anaplastic Large Cell Lymphoma (ALCL) Relapsed/Refractory Mantle Cell Lymphoma (MCL) and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)

Phase 2
16 Years
Not Enrolling

Thank you

Trial Information

A Phase II Study of 17 -AAG in Patients With RelapsedRefractory CD30 + Anaplastic Large Cell Lymphoma (ALCL) Relapsed/Refractory Mantle Cell Lymphoma (MCL) and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)



- Determine the complete and partial response rates and time to treatment failure in
patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell
lymphoma, or classical Hodgkin's lymphoma treated with
17-N-allylamino-17-demethoxygeldanamycin (17-AAG).


- Determine the safety of this drug in these patients.

- Determine the biologic effect of this drug on selected molecular targets in primary
lymphoma cells from these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to disease type
(anaplastic large cell lymphoma vs mantle cell lymphoma vs Hodgkin's lymphoma).

Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1,
4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease
progression or unacceptable toxicity. Patients experiencing disease regression after
completion of 8 courses may receive 2 additional courses of treatment beyond their maximal

After completion of study treatment, patients are followed every 3 months until disease

PROJECTED ACCRUAL: A total of 36-105 patients (12-35 per stratum) will be accrued for this
study within 2 years.

Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed relapsed/refractory
mantle cell lymphoma (MCL), anaplastic large cell lymphoma (ALCL), or classical
Hodgkin's lymphoma (HL).

2. Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as
greater than or equal to 20 mm.

3. Patients must have received at least one prior regimen and are not candidates for
stem cell transplantation.

4. Number of prior therapies: a) Primary refractory disease: Patients must have not
received more than 3 prior regimens (salvage therapy followed immediately by stem
cell transplant is considered one regimen). b) Relapsed from CR: no limit to number
of prior treatment regimens.

5. Single agent monoclonal antibody, cytokine therapy, or involved field radiation
therapy will not be counted in the number of prior therapies (because these
treatments are repeatedly administered and are devoid of serious toxicity). All prior
treatments will be recorded. Patients who received prior antibody therapy within 3
months of 17-AAG treatment will be identified.

6. Patients must have fully recovered from any significant toxicity associated with
prior surgery, radiation treatments, chemotherapy, biological therapy, autologous
stem cell transplantation (ASCT), or investigational drugs

7. Age greater than or equal to 16 years. Because no dosing or adverse event data are
currently available on the use of 17-AAG in pediatric patients, children who are
younger than 16 years old are excluded from this study but will be eligible for
future pediatric single-agent trials, if applicable.

8. ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to

9. Patients must have normal organ and marrow function as defined below: a) absolute
neutrophil count >/= 1,500/mL b) platelets >/= 75,000/mL c) total bilirubin within
normal institutional limits d) AST(SGOT)/ALT(SGPT) limit of normal e) creatinine within normal institutional limits.

10. The effects of 17-AAG on the developing human fetus at the recommended therapeutic
dose are unknown. For this reason, women of child-bearing potential and men must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately. Similarly, should a female
partner of a male patient become pregnant while he is on study,

11. Continuation from # 11: he should notify his treating physician immediately.

12. Understand and provide signed informed consent.

13. Patients receiving warfarin should be able to switch to low molecular weight heparin
while receiving 17-AAG therapy

Exclusion Criteria:

1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C, and 12 weeks for radio-immunotherapy) prior to entering
the study or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier.

2. Patients may not be receiving any other investigational agents.

3. Patients with known CNS lymphoma should be excluded from this clinical trial because
of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse

4. Prior allogeneic stem cell transplant because of their poor prognosis (Prior
autologous stem cell transplant is not an exclusion).

5. Known history of HIV infection or AIDS. Because patients with immune deficiency are
at increased risk of lethal infections when treated with marrow-suppressive therapy.
Furthermore, HIV-positive patients receiving combination anti-retroviral therapy are
excluded from the study because of possible pharmacokinetic interactions with 17-AAG.
Appropriate studies will be undertaken in patients receiving combination
anti-retroviral therapy when indicated.

6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

7. History of allergic reaction to eggs, because 17-AAG is formulated using egg

8. Patients with currently "active" second malignancy other than non-melanoma skin
cancer or carcinoma in-situ of the cervix are not to be registered. Patients are not
considered to have a currently "active" malignancy if they have completed therapy and
are considered by their physician to be at less than 30% risk of relapse.

9. Pregnant and lactating nursing women are excluded from this study because of unknown
risks of 17-AAG to fetus and infants

10. Patients with pulmonary lymphoma will be excluded.

11. Patients with symptomatic pulmonary disease requiring medication. (dyspnea, dyspnea
on exertion, paroxysmal nocturnal dyspnea, oxygen requirement and significant
pulmonary disease, including chronic obstructive/restrictive pulmonary disease).

12. Patients pulmonary status is sufficiently compromised, i.e., Carbon Monoxide
Diffusing Capacity (DLCO) less than or equal to 80%.

13. Patients with a prior history of chest radiation, a prior history of cardiac or
pulmonary toxicity after receiving anthracyclines such as doxorubicin, daunorubicin,
mitoxantrone, bleomycin or carmustine/bis-chloronitrosourea (BCNU).

14. Patients with greater than or equal to grade 2 pulmonary or cardiac symptoms prior to
study entry.

15. The use of concomitant medications that prolong or may prolong QTc.

16. Patients who have significant cardiac disease including heart failure that meets New
York Heart Association (NYHA) class III and IV definitions (see Appendix I), history
of myocardial infarction within one year of study entry, uncontrolled dysrhythmias,
or poorly controlled angina.

17. Patients who have a history of serious ventricular arrhythmia (VT or VF, >/= 3 beats
in a row), QTc >/= 450 msec for men and 470 msec for women, or LVEF
18. No history of prior radiation that potentially included the heart in the field

19. No active ischemic heart disease within 12 months.

20. No history of uncontrolled dysrhythmias or requiring antiarrythmic drugs.

21. No congenital long QT syndrome.

22. No left bundle branch block.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Patients With Response

Outcome Description:

Number of participants who experience complete response or partial response. Partial Response=>50% decrease in lympho node masses. Complete Response=>-75% decrease in lymph node masses.

Outcome Time Frame:

Baseline to time to best response; Every 6 weeks

Safety Issue:


Principal Investigator

Anas Younes, MD

Investigator Role:

Study Chair

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

February 2005

Completion Date:

April 2010

Related Keywords:

  • Lymphoma
  • anaplastic large cell lymphoma
  • recurrent adult Hodgkin lymphoma
  • recurrent mantle cell lymphoma
  • 17-N-allylamino-17-demethoxygeldanamycin
  • 17-AAGCD30+
  • Anaplastic Large Cell Lymphoma
  • ALCL
  • Classical Hodgkin's Lymphoma
  • HL
  • heat shock protein
  • HSP
  • HSP90
  • Tanespimycin
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Mantle-Cell



M. D. Anderson Cancer Center at University of Texas Houston, Texas  77030-4009